Trial Profile
Efficacy and safety of adalimumab (humira) in patients with peripheral spondyloarthritis without ankylosing spondylitis or psoriatic artritis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Aug 2015
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Spondylarthritis
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms TIPES
- 05 Aug 2015 Results of ABILITY-2 and TIPES study published in the Annals of the Rheumatic Diseases.
- 11 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 11 Nov 2012 Primary endpoint 'Patient-Global-Assessment' has been met.